How Much Does Increlex Cost?

Published on April 29, 2026 | Written by Alec Pow
This article was researched using 14 sources. See our methodology and corrections policy.

Increlex is a specialty injectable used for a small set of pediatric growth disorders. Families often see it handled through a specialty pharmacy, with refrigerated shipping and insurer paperwork before the first fill. Public transparency data shows a wholesale list figure in the mid four figures per vial, but the amount a family pays can be far lower or far higher depending on coverage rules and dose size.

Most prescriptions are billed as a vial-based drug claim, then any other services land elsewhere on the bill. A plan may treat it as a pharmacy benefit fill, or a medical benefit drug that uses a HCPCS code, and the route can change patient cost sharing. The listed price is not the same as a negotiated insurer allowance, and specialty pharmacies may add handling steps that do not show up at the clinic. This is pricing reporting, not medical advice.

Increlex fills are usually priced per vial and dispensed through a specialty pharmacy after prior authorization, with the claim often routed through a PBM-managed pharmacy benefit or, in some plans, through the medical benefit. The patient share can shift with specialty-tier coinsurance, deductible timing, and a dose change that alters how many vials ship each month. Cold-chain delivery and network rules can also affect when the first shipment is released.

Expect a multi-thousand-dollar vial, with insurance rules driving the swing.

How Much Does Increlex Cost?

Jump to sections

Three public reference points anchor this estimate. On a state transparency list, Increlex 40 mg/4 mL is shown at $3,676.25 per unit as of Jan. 22, 2026, which works out to $91.91 per mg (3,676.25 divided by 40) and $44,115 for 12 vials (3,676.25 multiplied by 12). A public-program specialty SMAC file shows $1,111.53600 for INCRELEX INJ 40MG/4ML, effective Jan. 27, 2025. A price guide listing says eligible commercially insured patients may pay as little as $0 per prescription through the manufacturer’s copay support.

• WAC reference per vial $3,676.25
• Illinois SMAC reference $1,111.53600
• Commercial copay program floor $0

What you’re actually buying

Increlex is the brand form of mecasermin, a lab-made version of insulin-like growth factor 1. It is prescribed for children with growth failure tied to severe primary IGF-1 deficiency, or for the rare case of growth hormone gene deletion with neutralizing antibodies to growth hormone.

Treatment is given by subcutaneous injection and dosing follows weight, so refill needs can change as a child grows. It is not a catch-all for short stature, and it is not used as a general substitute for growth hormone therapy. The practical purchase is ongoing access to a biologic medicine that has to be stored cold and dispensed with a tight chain of custody. The current U.S. label record on the current label record lists Eton Pharmaceuticals as the packager and shows an update dated Oct. 1, 2025.

Families also pay in time. Training on injection technique, glucose checks around meals, and regular endocrinology follow-up tend to be part of the care plan. Those items show up as separate charges even when the drug itself is approved. Some plans also require periodic documentation of growth response.

Increlex vs growth hormone options

Increlex sits in the IGF-1 lane, not the growth hormone lane. A child can have low growth velocity because the body does not make enough growth hormone, because the body cannot respond to growth hormone, or because nutrition and other conditions limit growth. Mecasermin is aimed at the severe primary IGF-1 deficiency scenario, which is why many payer files treat it separately from somatropin products. The decision is not a shopping exercise across interchangeable brands, it is driven by diagnosis and lab work.

A growth hormone prescription can still be the right therapy for growth hormone deficiency, and in some plans it sits on a different coverage tier with different rebates and contracting. A public reimbursement review describes mecasermin as therapy for a rare pediatric condition and separates it from growth hormone use, which is the same split U.S. insurers use in prior authorization and appeals. For budgeting, the key point is that switching therapies is a clinical decision, and the cost path changes with it. A new deductible clock can appear even when care stays the same after plan changes.

Price signals for Increlex in the U.S. market

Those figures are not what every buyer pays, but they show scale. WAC is a manufacturer list metric, and insurance pricing is often a negotiated allowed amount plus patient cost sharing. Cash-price tools such as pharmacy cash listings can show wide sticker-price differences by location and pharmacy, even when the same vial size is used.

Reference	What it is	Figure	Date
Nevada WAC list	WAC per unit	$3,676.25	Jan. 22, 2026
Illinois Specialty SMAC	State maximum	$1,111.53600	Jan. 27, 2025
Manufacturer copay support	Program floor	$0	no date shown

State maximums and copay programs can pull the patient number away from a list metric, and the gap can run both directions depending on plan design. If you are insured, ask for the allowed amount and coinsurance rate before the specialty pharmacy ships, and document the answer for the next refill so you can spot changes quickly later.

How the specialty-pharmacy fill gets billed

Even when the drug itself is a single vial, the claim trail can split. A specialty pharmacy may bill the drug, then bill supplies like syringes, alcohol wipes, and sharps containers through the pharmacy benefit, and those items may or may not share the same deductible bucket. Some insurers route the drug through the medical benefit, which can add a separate prior authorization team and a different claim form. Illinois describes this sort of pricing logic in its reimbursement rules PDF, which notes claims can be paid at the lower of several benchmarks.

Families can also see office visit charges when a clinic trains caregivers or checks injection sites. A visit fee is outside the drug claim, similar to what shows up in walk-in pricing like MinuteClinic visit costs and in procedure billing like knee gel injection pricing. If a plan requires early doses to be observed, facility fees can be the surprise. Ask the dispensing pharmacy which parts of the fill are billed under the drug NDC and which are billed as separate supply items, since that can change what a receipt looks like.

Ask early.

Insurance vs self-pay for Increlex

Insurance is where the gap opens. A plan can cover Increlex yet still leave a high patient share until the deductible is met, because specialty-tier coinsurance is based on the allowed amount, not a coupon card price. Prior authorization drives continuity. A coverage policy PDF lays out criteria tied to the FDA-labeled pediatric indication and notes the drug may be handled under either the pharmacy or medical benefit.

Self-pay can show up during a plan change or an out-of-network pharmacy mismatch. In that situation, the invoice may track close to a list figure, and families look to appeals or assistance. Some specialty drugs show similar cost sharing, as seen in lupus medication costs. Coverage paperwork matters.

Mini cases

• Commercial plan with copay support, pharmacy collects little at pickup, deductible credit may stay small.
• Commercial plan early in the year, coinsurance hits until deductible is met, first shipment is the stingy one.
• Medicaid style coverage, state maximum sets the claim ceiling, network pharmacy access and renewals still apply.

Ask the plan which benefit channel applies before the first shipment arrives at home.

Dose math

Increlex dosing is weight-based, and the label sets a starting range and a maximum. Clinicians may adjust dose after hypoglycemia episodes or other reactions. Dose changes shift vial need.

To estimate a refill, translate mg per kg into mg per month, then into vials. The same label also drives days-supply calculations at the specialty pharmacy, which can matter when a plan limits early refills or requires a new prior authorization after a plan change.

Worked example

1. Pick the dose in mg per kg per injection from the prescription.
2. Multiply by 2 injections per day to get mg per kg per day.
3. Multiply by 30 days to get mg per kg-month.
4. Divide by 40 mg per vial to estimate vials per kg-month.

Multiply that by body weight to estimate vial count.

Copay cards and patient assistance

For many families, assistance is about timing and eligibility, not coupons. Copay cards are often limited to commercial insurance, and some plans use accumulator or maximizer features that can block the card from counting toward the deductible. The manufacturer’s support resources page lists the hub and assistance contacts used for benefits investigations and refill coordination.

Patient assistance programs for the uninsured or under-insured may exist through non-profits or the manufacturer, but the eligibility rules vary and often require income documentation. Keep a copy of the prior authorization approval letter and the specialty pharmacy’s denial notes. Those papers tend to matter when a refill is delayed by a plan change or a claim reversal. If a plan routes Increlex under the medical benefit, ask whether assistance can still be applied.

Why Increlex pricing moved

In February 2025, Increlex showed up in a list-price change report as one of the largest movers. A WAC-change report lists a 150% WAC increase for Increlex in February 2025 and ties the timing to the product’s ownership shift. A change in ownership can bring new contracting and updated payer files, and it can also change the NDC on claims, which can trigger a new prior authorization file even when the drug and dose are unchanged.

For a household budget, re-check benefits at plan renewal or job changes. If an insurer switches the specialty pharmacy, a refill can be delayed by a new benefits investigation. Ask the clinic team for the NDC and the billing channel that the insurer expects, then confirm which coinsurance rate applies before the next shipment is released. Vials add up fast. When a new owner updates list price, PBMs and plans can respond with new prior authorization questions, new specialty-tier placement, or new step rules, so the next refill is the time to confirm coverage in writing.

Who this cost makes sense for

Coverage rules and dosing drive the bill.

Makes sense if

• Diagnosis matches labeled severe primary IGF-1 deficiency.
• In-network specialty pharmacy can ship refrigerated vials reliably.
• Budget can cover deductible and coinsurance early in year.

Doesn’t make sense if

• Clinician is choosing growth hormone therapy for GH deficiency.
• Specialty pharmacy is out of network, leaving cash pay.
• Cold storage or twice-daily injections are not workable.

What we verified

• Checked prescribing info page for current indication wording and label update metadata.
• Confirmed asset purchase filing for timing details in Eton’s acquisition paperwork.
• Cross-referenced acquisition announcement for the seller and buyer named in the transaction.

Answers to Common Questions

Is WAC what I pay?

No. WAC is a list figure. Your bill depends on allowed amount, deductible status, and coinsurance rules today.

Can it run under medical benefit?

Yes, some plans do that. The claim uses different codes and may require a different prior authorization review path.

Does a co-pay card count toward deductible?

Not always. Some plans apply accumulator rules, so the card lowers the register amount but does not credit your deductible in full.